Journal
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 86, Issue 8, Pages 3568-3573Publisher
ENDOCRINE SOC
DOI: 10.1210/jc.86.8.3568
Keywords
-
Categories
Funding
- NCRR NIH HHS [MO1-RR00070] Funding Source: Medline
- NIDDK NIH HHS [DK-42482, DK-07217-24] Funding Source: Medline
- NIMH NIH HHS [R01-MH50604] Funding Source: Medline
Ask authors/readers for more resources
An extremely ill patient, with Cushing's syndrome caused by an ACTH-secreting pituitary macroadenoma, experienced complications of end-stage cardiomyopathy, profound psychosis, and multiple metabolic disturbances. Initially treated unsuccessfully by a combination of conventional surgical, medical, and radiotherapeutic approaches, he responded dramatically to high-dose long-term mifepristone therapy (up to 25 mg/kg.d). Treatment efficacy was confirmed by the normalization of all biochemical glucocorticoid-sensitive measurements, as well as by the significant reversal of the patient's heart failure, the resolution of his psychotic depression, and the eventual unusual return of his adrenal axis to normal His 18-month-long mifepristone treatment course was notable for development of severe hypokalemia that was attributed to excessive cortisol activation of the mineralocorticoid receptor, which responded to spironolactone administration. This case illustrates the efficacy of high-dose long-term treatment with mifepristone in refractory Cushing's syndrome. The case also demonstrates the potential need for concomitant mineralocorticoid receptor blockade in mifepristone-treated Cushing's disease, because cortisol levels may rise markedly, reflecting corticotroph disinhibition, to cause manifestations of mineralocorticoid excess.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available